Education
About Us
Working with TipRanks
Follow Us
Genus plc (GB:GNS)
:GNS
GNS Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,424.00p - 2,160.00p
Previous CloseN/A
Volume9.41K
Average Volume (3M)172.02K
Market Cap
£1.35B
Enterprise ValueN/A
Total Cash (Recent Filing)£42.50M
Total Debt (Recent Filing)£291.20M
Price to Earnings (P/E)147.6
Beta1.73
Next Earnings
Sep 04, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 06, 2025Dividend Yield1.58%
Share Statistics
EPS (TTM)0.39
Shares Outstanding66,036,770
10 Day Avg. Volume189,307
30 Day Avg. Volume172,019
Financial Highlights & Ratios
PEG Ratio-2.07
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio88.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,962.50Price Target Upside-4.73% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Genus plc News
PremiumCompany Announcements
Genus plc Appoints J.P. Morgan as New Financial Adviser
PremiumCompany Announcements
Genus plc Updates Total Voting Rights Information
PremiumCompany Announcements
Genus plc Achieves FDA Approval for PRRS Resistant Pig
PremiumCompany Announcements
Genus plc Announces Change in Major Shareholder Voting RightsPremiumCompany Announcements
Genus PLC Announces Change in Voting Rights StructurePremiumCompany Announcements
Genus plc Announces Vesting of Share Awards for Executive Team Member
PremiumCompany Announcements
Genus PLC Announces Change in Voting Rights Held by BlackRockBulls Say, Bears Say
Bulls Say
FDA ApprovalGenus has secured FDA approval for its PRP gene edited pigs for use.
Financial PerformanceThe company reported better-than-expected performance in the first half of FY25, with significant growth in adjusted profit before tax.
Trading UpdateGenus has announced that adjusted profit before tax for the first half of FY25 will be at least £35m, which is ahead of expectations.
Bears Say
Economic WeaknessThere is caution due to continued economic weakness in China and the possibility of tariff wars, which could impact the business negatively.
Regulatory ChallengesUncertainty exists due to important regulatory and commercial hurdles for the PRP programme, affecting near-term confidence.
Stock ValuationThe company's shares trade at premium multiples compared to peers, despite having similar growth rates and lower margins.
Options Prices
Currently, No data available
---
Ownership Overview
0.35% Insiders
12.74%
Mutual Funds
― Other Institutional Investors
79.67% Public Companies and
Individual Investors
GNS FAQ
What was Genus plc’s price range in the past 12 months?
Genus plc lowest share price was 1424.00p and its highest was 2160.00p in the past 12 months.
What is Genus plc’s market cap?
Genus plc’s market cap is £1.35B.
When is Genus plc’s upcoming earnings report date?
Genus plc’s upcoming earnings report date is Sep 04, 2025 which is in 98 days.
How were Genus plc’s earnings last quarter?
Genus plc released its earnings results on Feb 27, 2025. The company reported 0.394p earnings per share for the quarter, beating the consensus estimate of N/A by 0.394p.
Is Genus plc overvalued?
According to Wall Street analysts Genus plc’s price is currently Overvalued.
Does Genus plc pay dividends?
Genus plc pays a Annually dividend of 31.999p which represents an annual dividend yield of 1.58%. See more information on Genus plc dividends here
What is Genus plc’s EPS estimate?
Genus plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genus plc have?
Genus plc has 66,036,770 shares outstanding.
What happened to Genus plc’s price movement after its last earnings report?
Genus plc reported an EPS of 0.394p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.372%.
Which hedge fund is a major shareholder of Genus plc?
Currently, no hedge funds are holding shares in GB:GNS
Genus plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£1,962.50 (-4.73% Downside)
£1,962.50 (-4.73% Downside)
Blogger Sentiment
Bullish
GB:GNS Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth £427.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.46%
12-Months-Change
Fundamentals
Return on Equity
-0.73%
Trailing 12-Months
Asset Growth
-6.45%
Trailing 12-Months
Company Description
Genus plc
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in reproductive, and other technical services to farmers. Genus plc has a strategic collaboration with Beijing Capital Agribusiness Co. Ltd to pursue the porcine reproductive respiratory syndrome virus resistant regulatory and development work in China. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
GNS Stock 12 Month Forecast
Average Price Target
1,962.50p
▼(-4.73%Downside)
Technical Analysis
Bioventix
―
PureTech Health
―
Oxford BioMedica
―
4basebio UK Societas
―
Oxford Nanopore Technologies PLC
―